Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Under this strategic arrangement, Cipla will distribute and promote Yurpeak, marking the second brand of tirzepatide to be ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...

Lilly and Cipla announce a distribution agreement for Yurpeak, a drug for type 2 diabetes and weight management, enhancing ...

Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...